Skip to main content
. 2018 Mar 30;15(6):8627–8634. doi: 10.3892/ol.2018.8399

Figure 3.

Figure 3.

Anti-tumor effects of bevacizumab treatment in HSC-3 xenografts. Following tumor formation, mice were grouped and treated with either saline (n=6), bevacizumab (n=6) or left untreated (n=6). Tumor volumes were calculated as aforementioned. Each data point represents the mean tumor volume ± SD. Inhibition of tumor growth in mice treated with bevacizumab was increased compared with that in mice treated with saline or left untreated (P<0.01). **P<0.01.